Article
Effect of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of tacrolimus in the treatment of nephrotic syndrome.
BMC pharmacology & toxicology - 3 Apr 2018
Li Min, Xu Min, Liu Wei, Gao Xin
Abstract excerpt
BACKGROUND: The efficacy of tacrolimus (TAC) is variable in the treatment of nephrotic syndrome (NS), which might be related to genetic variation among patients. Therefore, we aim to investigate the effects of CYP3 A4, CYP3 A5 and ABCB1 gene polymorphisms on the clinical efficacy of TAC in the treatment of NS patients. Methods 100 NS patients were treated with TAC and prednisone and followed up for 3 months....
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.